IL13RA1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt the IL13RA1 gene. This product provides a mixed population of cells carrying diverse loss-of-function modifications at the IL13RA1 locus, generated without single-cell cloning, thereby preserving genetic heterogeneity while abolishing functional IL13RA1 protein expression. The polyclonal format avoids clonal artifacts and enables robust, population-level interrogation of IL13RA1-dependent signaling within a physiologically relevant lung cancer background.
A-549 cells are an established epithelial cell line isolated from human lung carcinoma tissue, widely employed as a model system in cancer biology, drug metabolism, and viral infection studies. These adherent cells exhibit characteristics of type II pneumocytes and retain key oncogenic pathways, making them a valuable tool for investigating signaling mechanisms that contribute to lung adenocarcinoma progression and therapeutic resistance.
IL13RA1 encodes the alpha-1 subunit of the interleukin-13 receptor, which pairs with IL4R to form the functional type II IL-4 receptor complex. Upon binding of extracellular ligands IL-13 or IL-4, the receptor activates associated Janus kinases JAK1 and TYK2, leading to phosphorylation of the transcription factor STAT6. Activated STAT6 dimerizes, translocates to the nucleus, and drives expression of downstream target genes such as eotaxin, SOCS1, and components involved in IgE class switching and mucus production. This signaling cascade is further regulated by upstream factors IL-13, IL-4, and GATA3, and can be inhibited by the negative feedback regulator SOCS1. Disruption of IL13RA1 in the knockout polyclonal cells eliminates ligand-induced STAT6 phosphorylation and downstream transcriptional responses, creating a clean loss-of-function model.
In the context of A-549 lung adenocarcinoma cells, IL-13 signaling has been implicated in tumor-promoting inflammation, epithelial-mesenchymal transition, and modulation of the tumor microenvironment. Knockout of IL13RA1 abrogates the cellular response to type II IL-4 receptor activation, enabling researchers to dissect the contribution of IL-13/IL-4-driven pathways to processes such as proliferation, migration, and chemoresistance. This model is particularly relevant for studying how cytokine signaling intersects with oncogenic pathways in non-small cell lung cancer and for evaluating the role of allergic inflammatory mediators in tumor biology.
Key research applications include quantitative analysis of STAT6 phosphorylation via western blotting, profiling IL-13 target gene expression by RT-qPCR, and flow cytometric validation of receptor loss. Researchers can utilize these cells in migration and invasion assays, drug sensitivity screens with JAK inhibitors, and global transcriptomic analyses by RNA-seq to map IL13RA1-dependent networks. The model also supports asthma and allergic inflammation studies where A-549 cells are used as a surrogate for airway epithelia. For further information or customized inquiries, please contact Ascent Research.
